Back to top
more

Ligand Pharmaceuticals (LGND)

(Real Time Quote from BATS)

$90.90 USD

90.90
37,697

+4.02 (4.63%)

Updated Jul 9, 2024 11:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ligand (LGND) Down 14% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales

by Zacks Equity Research

Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.

Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of 34.29% and -15.61%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

John Blank headshot

Will Central Banks Start to Care About Fundamentals?

by John Blank

Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.

Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Ligand (LGND) Down 21.3% Since Last Earnings Report?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ligand (LGND) Q4 Earnings & Sales Top, 2021 Guidance Raised

by Zacks Equity Research

Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.

Daniel Laboe headshot

WallStreetBets: The Big Short-Squeeze

by Daniel Laboe

Will WallStreetBets mark the end of short-selling as we know it, or was GME a one-time sideshow in the market?

Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More

by Zacks Equity Research

Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.

Ligand (LGND) Up 3.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations. Stock down.

Ligand Pharmaceuticals (LGND) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of -1.89% and -8.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Ligand (LGND) This Earnings Season?

by Zacks Equity Research

Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.

    Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    by Zacks Equity Research

    Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Bristol Myers to Buy MyoKardia to Aid Cardiovascular Franchise

    by Zacks Equity Research

    Bristol Myers (BMY) offers $13.1 billion to acquire MyoKardia for diversifying its cardiovascular product portfolio. The transaction is expected to close in the fourth quarter of 2020.

    AMAG (AMAG) to be Acquired by Covis Group for $647 Million

    by Zacks Equity Research

    AMAG (AMAG) is set to be acquired by Covis Group for approximately $647 million.

    bluebird's MAA for Elivaldogene Autotemcel Accepted by EMA

    by Zacks Equity Research

    bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.

    ADMA Biologics (ADMA) Surges: Stock Moves 8.6% Higher

    by Zacks Equity Research

    ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

    LGND or ALKS: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    LGND vs. ALKS: Which Stock Is the Better Value Option?

    Ligand Pharmaceuticals Enters Oversold Territory

    by Zacks Equity Research

    Ligand Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

    LGND or ALKS: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    LGND vs. ALKS: Which Stock Is the Better Value Option?

    Ligand (LGND) Down 13.7% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    LGND vs. ILMN: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    LGND vs. ILMN: Which Stock Is the Better Value Option?

    LGND vs. ILMN: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    LGND vs. ILMN: Which Stock Is the Better Value Option?

    Ligand (LGND) Beats on Q2 Earnings & Sales, Raises View

    by Zacks Equity Research

    Ligand (LGND) reports better-than-expected second-quarter 2020 earnings and revenues. Stock up.